Prebiotic‑stimulated GABA production by indigenous Lactiplantibacillus predicts SSRI response in depression
Hypothesis
Specific prebiotic fibers that selectively stimulate indigenous GABA‑producing Lactiplantibacillus plantarum strains increase luminal GABA, which in turn predicts greater clinical response to selective serotonin reuptake inhibitors (SSRIs) in depression.
Mechanistic Rationale
Prebiotics such as galactooligosaccharides (GOS) are fermented by gut microbes to short‑chain fatty acids (SCFAs) like butyrate. Butyrate acts as a histone deacetylase inhibitor, upregulating the gadB/gadC glutamate decarboxylase pathway in Lactobacillus, thereby boosting GABA synthesis 2. Elevated GABA can activate vagal afferents and modulate central neurotransmission, potentially synergizing with SSRI‑induced serotonergic signaling. This mechanistic link explains why generic prebiotic supplementation shows only weak antidepressant effects 1—only subsets of individuals harboring GABA‑competent Lactobacillus strains would benefit.
Testable Predictions
-
Baseline fecal metatranscriptomic abundance of gadB/gadC in Lactiplantibacillus correlates with subsequent SSRI response.
-
Administration of a GOS prebiotic for 4 weeks raises fecal GABA levels and enriches Lactobacillus gadB expression, but only in participants who initially possess the GABA‑producing genotype.
-
The magnitude of GABA increase mediates the improvement in Hamilton Depression Rating Scale (HAM‑D) scores after SSRI treatment, independent of changes in overall microbial diversity.
Experimental Design
A double‑blind, randomized, placebo‑controlled trial enrolling 120 medication‑naïve adults with moderate depression. Participants are stratified by baseline Lactobacillus GABA‑gene abundance (high vs low). Each stratum receives either GOS (10 g/day) or placebo for 4 weeks, followed by an 8‑week open‑label SSRI (escitalopram 10 mg/day). Primary outcomes: change in HAM‑D at week 12. Secondary outcomes: fecal GABA concentration (LC‑MS), Lactobacillus gadB expression (metatranscriptomics), and SCFA profile. Mediation analysis will test whether GABA change predicts HAM‑D improvement.
Potential Implications
If confirmed, the approach would enable a biomarker‑driven, microbiome‑guided step before prescribing SSRIs, addressing the current lack of validation for routine microbiome testing 3. It also clarifies why broad prebiotic recommendations have yielded inconsistent results 1,8 and directs future efforts toward strain‑specific fiber selection rather than generic supplementation.